A first-in-patient, multi-ascending dose trial of PRS-343 for the treatment of HER-2 positive solid tumors
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2017
At a glance
- Drugs PRS 343 (Primary)
- Indications Bladder cancer; Breast cancer; Gastrointestinal cancer; Solid tumours
- Focus Adverse reactions; First in man
- 09 Aug 2017 According to a Pieris Pharmaceuticals media release, the company expects to to dose first patient in this trial very soon.
- 04 Apr 2017 According to a Pieris Pharmaceuticals media release, data informing the design of this trial at the 2017 Annual Meeting of the American Association for Cancer Research (AACR).
- 20 May 2016 New trial record